- $701.80m
- $461.67m
Brief: Sagimet Biosciences reports fourth-quarter net loss of $16.2 mln
Brief: Sagimet Biosciences receives FDA nod to begin testing its therapy for acne
Brief: Sagimet Biosciences Announces Oral Presentation At The Mash Pathogenesis And Therapeutic Approaches Keystone Symposium
U.S. STOCKS ON THE MOVE-Middleby, Boeing, Aurora Mobile
U.S. STOCKS ON THE MOVE-Sagimet Biosciences, Sage Therapeutics, Qorvo
U.S. STOCKS ON THE MOVE-Tevogen Bio, Akero Therapeutics, AspenTech
JonesTrading starts coverage on drug developer Sagimet with 'buy' rating
Brief: Sagimet Biosciences Announces Oral Presentation At The 9th Annual MASH-TAG 2025 Conference
U.S. STOCKS ON THE MOVE-US energy sector, Oshkosh, Meta
Sagimet rises as Oppenheimer initiates coverage with 'outperform'
U.S. RESEARCH ROUNDUP- Doordash, Sagimet Biosciences, Ulta Beauty
Brief: Sagimet Biosciences Announces Successful Completion Of End-Of-Phase 2 Interactions With FDA On The Development Of Denifanstat For Mash Phase 3 Program Initiation Expected By End Of 2024
U.S. STOCKS ON THE MOVE-Paychex, Dine Brands, Pinterest
U.S. STOCKS ON THE MOVE-Sagimet, Datadog, Clorox
Sagimet jumps on FDA's 'breakthrough therapy' tag for liver disease treatment
Brief: Sagimet Biosciences Files For Mixed Shelf Of Up To $300 Mln
Brief: Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
Brief: Sagimet Biosciences Announces Completion Of Phase 1 Hepatic Impairment Study With FASN Inhibitor Denifanstat
Brief: Sagimet Biosciences Announces Appointment Of Tim Walbert And Paul Hoelscher To Board Of Directors